Deal Watch: Ferring Enters New Therapeutic Area With Phase III Sciatica Candidate
Trek Therapeutics expands its HCV pipeline by in-licensing polymerase inhibitor from Medivir. ProMetic gains cash, tax offsets and physical plant by acquiring fellow Canadian firm Telesta for pennies per share, while Cell Medica inks its second academic cancer immunotherapy collaboration of 2016, this time with University College London.
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Aug. 13 and Aug. 29. Deal Watch is supported by deal intelligence from Strategic Transactions.
Switzerland's Ferring BV has acquired exclusive worldwide rights, except for Japan, to a Phase III candidate for sciatica from...